Title |
Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report
|
---|---|
Published in |
Journal of Medical Case Reports, July 2017
|
DOI | 10.1186/s13256-017-1334-z |
Pubmed ID | |
Authors |
Hélène Pluchart, Julian Pinsolle, Julien Cohen, Gilbert R. Ferretti, Pierrick Bedouch, Matteo Giaj Levra, Anne-Claire Toffart, Denis Moro-Sibilot |
Abstract |
Nivolumab, a monoclonal antibody targeting the programmed death-1 receptor, is indicated in locally advanced or metastatic non-small cell lung cancer, with progression after platinum-based chemotherapy. Up-to-now, few data are available concerning brain activity of this treatment and concomitant use of corticosteroids. A 64-year-old caucasian man with a pulmonary adenocarcinoma associated with brain metastases received four courses of nivolumab in concomitance with a high dose of corticosteroids for his neurologic symptoms. He experienced a partial response in his brain and chest with an improvement in his general condition. Nivolumab was effective in shrinking symptomatic brain metastases, and metastases at other sites, in a patient with non-small cell lung cancer and first-line chemotherapy failure. The effect of nivolumab was obtained despite concomitant high-dose corticosteroid therapy. Combined nivolumab and high-dose corticosteroid therapy did not induce unexpected adverse events. Nivolumab and concomitant high-dose corticosteroid therapy was found to be efficient and well tolerated. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 30 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 5 | 17% |
Student > Master | 4 | 13% |
Student > Postgraduate | 3 | 10% |
Student > Doctoral Student | 2 | 7% |
Researcher | 2 | 7% |
Other | 6 | 20% |
Unknown | 8 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 37% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
Nursing and Health Professions | 2 | 7% |
Biochemistry, Genetics and Molecular Biology | 1 | 3% |
Agricultural and Biological Sciences | 1 | 3% |
Other | 3 | 10% |
Unknown | 9 | 30% |